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Abstract
Background: Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events.
The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and
rosuvastatin in patients with hypertension and hypercholesterolemia.
Methods: We conducted a randomized double-blind and parallel-group trial. Patients who met eligible criteria
after 4 weeks of therapeutic life change were randomly assigned to the following groups.
1) co-administration of fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV), 2) fimasartan 120 mg (FMS) alone 3)
rosuvastatin 20 mg (RSV) alone. Drugs were administered once daily for 8 weeks.
Results: Of 140 randomized patients, 135 for whom efficacy data were available were analyzed. After 8 weeks of
treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP)
blood pressures than those in the group receiving RSV alone (both p < 0.001). Reductions in siSBP and siDBP were
not significantly different between the FMS/RSV and FMS alone groups (p = 0.500 and p = 0.734, respectively).
After 8 weeks of treatment, FMS/RSV treatment showed greater efficacy in percentage reduction of low-density
lipoprotein cholesterol (LDL-C) level from baseline than that shown by FMS alone treatment (p < 0.001). The
response rates of siSBP with FMS/RSV, FMS alone, and RSV alone treatments were 65.22, 55.56, and 34.09%,
respectively (FMS/RSV vs. RSV, p = 0.006). The LDL-C goal attainment rates with FMS/RSV, RSV alone, and FMS alone
treatments were 80.43%, 81.82%, and 15.56%, respectively (FMS/RSV vs. FMS, p < 0.001). Incidence of adverse drug
reactions with FMS/RSV treatment was 8.33%, which was similar to those associated with FMS and RSV alone
treatments.
Conclusion: This study demonstrated that the co-administration of fimasartan and rosuvastatin to patients with
both hypertension and hypercholesterolemia was efficacious and safe.
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Background
Hypertension and hypercholesterolemia are major risk
factors of cardiovascular disease (CVD) events. The co-
existence of both risk factors is quite common. The preva-
lence of coexistence was estimated to be 30% in an epide-
miologic study [1]. The co-existence of hypertension and
hypercholesterolemia can act additively or synergistically
to elevate CVD risk [2, 3]. Because of the increased risk of
CVD with comorbidities, guidelines have recommended
simultaneous treatment of both risk factors [4, 5]. Indeed,
long-term reduction of both serum total cholesterol (TC)
and systolic blood pressure (SBP) by 10% could reduce
major CVD events by 45% [6].
The beneficial effects for the prevention of CVD
events in most clinical trials have been obtained from
controlled adherence to study drugs. Poor adherence to
treatment is a problem in real practice, leading to in-
creased cardiovascular disease events [7, 8]. To improve
adherence to drug treatment, regimen simplification by
reducing the number of drugs and the frequency of
dosing has been found to be effective. Single pill
combination is one of the methods that can simplify
regimens and enhance adherence to treatment [9, 10].
The present study was a phase III trial to evaluate the
efficacy and safety of the co-administration of fimasartan
and rosuvastatin in patients with both hypertension and
hypercholesterolemia.
Methods
Patients
Patients (age 20–75 years) with hypertension (blood pres-
sure ≥ 140/90 mm Hg or currently on antihypertensive
medication) and dyslipidemia (defined in accordance with
the National Cholesterol Education Program Adult Panel
III (NCEP-ATP III) [11] or currently on lipid modifying
medications) were included. Exclusion criteria were a
mean sitting SBP (siSBP) ≥ 180 mmHg at screening
visit and/or sitting diastolic blood pressure (siDBP) ≥
110 mmHg; differences between arms ≥ 20 mmHg for
siSBP or ≥ 10 mmHg for siDBP; secondary hypertension;
secondary dyslipidemia (nephrotic syndrome, dysproteine-
mia, Cushing’s syndrome, and obstructive hepatopathy);
fasting triglyceride level at pre-randomization visit ≥
400 mg/dL; history of myopathy, rhabdomyolysis, and/or
creatinine kinase ≥ 2× upper limit of normal; history of
hypersensitivity to angiotensin receptor antagonist and/or
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors; gastrointestinal surgery or active
inflammatory gastrointestinal diseases potentially affecting
study drug absorption in the preceding 12 months; uncon-
trolled (glycated hemoglobin > 9% at pre-randomization
visit) or insulin-dependent diabetes mellitus; liver disease
(aspartate aminotransferase and/or alanine aminotransfer-
ase ≥ 2 × upper normal limit); hepatitis B (including
positive test for HBsAg) or hepatitis C-positive; impaired
function of kidney (serum creatinine ≥ 1.5 × upper nor-
mal limit); human immunodeficiency virus infection;
electrolyte imbalance (sodium level < 133 mmol/L or ≥
145 mmol/L or potassium level < 3.5 mmol/L or ≥
5.5 mmol/L); retinal hemorrhage; visual disturbance
or retinal microaneurysm within the past 6 months; his-
tory of abusing drugs or alcohol; ischemic heart disease
within the previous 6 months (angina pectoris, acute myo-
cardial infarction); peripheral vascular disease); percutan-
eous coronary intervention, or coronary artery bypass
graft within the previous 6 months; severe cerebrovascular
disease within previous 6 months (cerebral infarction, or
cerebral hemorrhage); New York Heart Association func-
tional class III and VI heart failure; clinically significant
cardiac arrhythmia; or history of any type of malignancy
within the previous 5 years; women in pregnancy, breast-
feeding, or child-bearing potential without no intention of
using a contraceptive.
Study design
This multicenter, randomized, double-blind, and parallel-
group trial was performed at 29 study centers in Korea.
Institutional Review Board of the participating institution
(Additional file 1: Table S1) and the Ministry of Food and
Drug Safety approved the study design. Written informed
consent was obtained from all patients. After screening,
patient who met the eligible criteria entered 4 weeks of
therapeutic life changes (TLC) consisting of detailed edu-
cation given by a study coordinator. During the 4 weeks of
TLC, patients who were already receiving lipid modifying
and/or antihypertensive medications discontinued taking
their lipid modifying medications for at least 4 weeks and
antihypertensive medications for at least 2 weeks prior to
randomization. After 4 weeks of TLC, patients who met
the inclusion criteria for randomization (Table 1) were
randomly assigned at a 1:1:1 ratio to receive one of
three treatments once daily for 8 weeks: 1) fimasartan
120 mg/rosuvastatin 20 mg (FMS/RSV); 2) fimasartan
120 mg (FMS); 3) rosuvastatin 20 mg (RSV) using a
sealed envelope with the randomization number. Study
drugs were supplied by Boryung Pharmaceutical Co. Ltd.
(Seoul, Republic of Korea). Randomization criteria of
dyslipidemia were based on NCEP-ATP III [11].
All patients were instructed to orally take the assigned
drug once daily in the morning for the study duration.
Prior to a scheduled visit, patients were instructed to fast
12 h without taking the study drug in the morning. At
each visit, three measurements of siSBP, siDBP, and
pulse rate were taken from the reference arm after a
5 min rest and with a 2 min interval between measure-
ments using a semi-automated sphygmomanometer
[HEM-7080IT, Omron Corporation, Kyoto, Japan] [12, 13].
The three siSBP and siDBP measurements were averaged.
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Fasting blood samples obtained during scheduled
visits were sent to the central laboratory (Seoul
Medical Science Institute, Seoul, Korea) for analysis
of TC, triglyceride, high-density lipoprotein choles-
terol (HDL-C), and low density lipoprotein cholesterol
(LDL-C) levels.
Efficacy evaluation
The primary efficacy points were comparing: 1) changes
from baseline in mean siSBP after 8 weeks of treatment
between the FMS/RSV and RSV treatment groups, and 2)
percentage change from baseline of mean LDL-cholesterol
after 8 weeks of treatment between the FMS/RSV and
FMS treatment groups.
The secondary efficacy points were comparing: 1)
changes from baseline in mean siSBP after 8 weeks of
treatment between the FMS/RSV and FMS alone treat-
ment groups, 2) percentage change from baseline of LDL-
cholesterol after 8 weeks of treatment between the FMS/
RSV and RSV treatment groups, 3) changes from baseline
in TC, HDL-C, and triglyceride levels after 8 weeks of
treatment, 4) changes from baseline in mean siDBP after
8 weeks of treatment, 5) blood pressure control rate (the
percentage of patients who reached mean siSBP <
140 mmHg after 8 weeks of treatment) and response rate
(the percentage of patients who reached a mean siSBP <
140 mmHg and/or a reduction of siSBP ≥ 20 mmHg from
baseline values after 8 weeks of treatment), and 6) the
percentage of patients achieving the LDL-C target level
after 8 weeks of treatment (goal attainment rate) accord-
ing to the NCEP-ATP III guidelines (high risk: LDL-C
level < 100 mg/dL; moderate/moderate high risk: LDL-C
level < 130 mg/dL; low risk: LDL-C level < 160 mg/dL) [11].
Safety evaluation
Assessment of safety and tolerability were conducted by
medical examination, patient reporting, and laboratory
tests (electrocardiography at baseline and the end of
week 8, blood and urine tests at baseline and the end of
week 8, pregnancy test at every visit). All adverse events
(occurrence and elimination dates, detailed nature,
duration, seriousness, intensity, significance, and rela-
tionship to the study drug) occurring during the study
period were recorded.
Sample size
This was a therapeutic confirmatory study to verify the
superiority of FMS/SRV treatment in terms of change in
mean siSBP (from baseline to week 8) compared to RSV
alone, and in terms of percentage change of LDL-C
(from baseline to week 8) compared to FMS alone.
Therefore, two statistical hypotheses were formulated
and the number of subjects was calculated. Total test
power for the whole hypothesis was set to 80% while the
two-sided significance level of each hypothesis was set to
5%. The test power for each hypothesis was set to 90%
without adjusting multiplicity.
It was assumed that the mean change in siSBP with
the FMS/RSV treatment was identical to that of the
FMS alone treatment of a previous study, and that the
mean change in siSBP of the RSV alone treatment was
identical to that of the placebo. The difference in the
mean and the standard deviation between the two treat-
ment groups were estimated using weighted mean and
pooled standard deviation based on the results of previ-
ous studies [14, 15]. The mean siSBP was lowered
−17.41 mmHg by FMS treatment and −7.34 mmHg by
placebo. The difference in siSBP lowering effect between
the two groups was 10.07 mmHg with a pooled standard
deviation of 12.91 mmHg. Required sample sizes were at
least 36 subjects per group. A total of 135 subjects
(45 subjects each for 3 groups) were considered in
order to make the sample size cutoff, working under
the assumption of a dropout rate of 20%.
The mean percent change of LDL-C in previous studies
was −57.0% in the RSV treatment alone and −3.6% in the
placebo. The difference in LDL-C lowering effect between
the two groups was 53.4% with the standard deviation
assumed to be 20% [16]. Required sample sizes in the
comparison of the LDL-C lowering effect were at least 4
Table 1 Inclusion criteria at randomization
Risk category Cardiovascular risk factorsa Randomization criteria
LDL-cholesterol (mg/dL) Averaged sitting SBP (mmHg)
Low risk 0 risk factors ≥160 and≤ 250 ≥140 and < 180
Moderate risk 1+ risk factors and 10 year risk < 10% ≥160 and≤ 250
Moderate high risk 1+ risk factors and 10-year risk from 10% to 20% ≥130 and≤ 250
High risk CHDb and CHD risk equivalentc ≥100 and≤ 250
aRisk factors: include cigarette smoking, hypertension (BP ≥ 140/90 mm Hg or on antihypertensive medication), low HDL cholesterol (<40 mg/dL), family history of
premature CHD (CHD in male first-degree relative < 55 years of age; CHD in female first-degree relative < 65 years of age), and age (men ≥ 45 years; women ≥ 55 years)
bCHD (coronary heart disease) includes history of myocardial infarction, unstable angina, stable angina, coronary artery procedures (angioplasty or bypass surgery),
or evidence of clinically significant myocardial ischemia
cCHD (coronary heart disease) risk equivalents include clinical manifestations of noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal
aortic aneurysm, and carotid artery disease [transient ischemic attacks or stroke of carotid origin or > 50% obstruction of a carotid artery]), diabetes, and 2+ risk factors
with 10-year risk for hard CHD > 20%
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subjects per group. Therefore, a total of 15 subjects (3
groups) were required under the assumption of a dropout
rate of 20%.
Finally, a total of 135 subjects were chosen as the
sample size because the sample size required for the
comparison of the siSBP lowering effect was greater than
that required for the comparison of the LDL-C lowering
effect.
Statistical analyses
For the main analysis of efficacy, full analysis set (FAS)
was used while per-protocol set (PPS) analysis was
additional. FAS included all subjects with at least one
efficacy evaluation result after baseline. Within the FAS,
PPS consisted of patients who completed the treatment
course without any significant protocol violations that
might affect efficacy outcomes. If any values in the
primary and secondary efficacy points were missed, the
Last-Observation-Carried-Forward imputation method
was used. The response rate and control rate were ana-
lyzed by using the Non-Response Imputation method to
process patients with missing data at the time point of
measurement as a non-responder.
The safety set included the patients who had been
administered the investigational product at least once
after randomization and had been assessed for safety at
least once. The safety analysis was conducted based on
the actual treatment group, regardless of the randomized
group. Safety assessment variables for missed data were
not imputed.
Using baseline values (blood pressure and LDL-C),
age, gender, and smoking status as covariates, analysis of
covariance (ANCOVA) was performed to test the differ-
ence in the two primary efficacy endpoints between
groups at 5% significance level (two-sided). In order to test
for differences within the treatment group, one sample t-
test for the percent change in LDL-C and paired t-test for
the change in siSBP were performed. If normality was not
satisfied, a Wilcoxon signed rank test was performed.
Descriptive statistics for the secondary efficacy end-
points were presented for treatment groups. One sample
t-test for the percentage change of LDL-C, TC, HDL-C
and TG from baseline within the treatment group, and
paired t-test for the change in siSBP and siDBP were
performed. If normality was not satisfied, Wilcoxon
signed rank test was performed.
The proportion and 95% confidence interval for the
response rate and control rate of siSBP, as well as the
goal attainment rate for LDL-C at week 8 were
presented. Using the treatment groups as factors and
baseline data, age, gender and smoking status as covari-
ates, the logistic regression analysis was performed for
the significant difference between monotherapy and
combination therapy group.
Additionally, the interactive effect was tested by using
an ANCOVA model in order to confirm the existence of
an interaction effect between the monotherapy and com-
bination treatment groups by variables. The combination
therapy group was determined to be superior to the mono-
therapy group if both variables in the combination therapy
group showed statistically significant superiority to the
monotherapy group as a result of an ANCOVA test.
Medical Dictionary for Regulatory Activities (MedDRA;
v 18.0) was used in coding adverse events. The percentage
of patients who experienced any adverse events between
groups was compared using Chi-square or Fisher's exact
tests. Incidence of adverse events was presented according
to severity and relationship with study drugs.
Fig. 1 Subject disposition and reasons for study discontinuation. Reasons for discontinuation included (1) withdrawal of consent, (2) protocol
violations, (3) lack of efficacy, (4) adverse events, and (5) other reasons. FMS: fimasartan; RSV, rosuvastatin. FMS/RSV: fimasartan 120 mg/rosuvastatin
20 mg treatment; FMS: fimasartan 120 mg alone treatment; RSV: rosuvastatin 20 mg alone treatment; FAS: full analysis set; PPS: per-protocol set
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Baseline characteristics were compared among the
treatment groups using Kruskal-Wallis test for continu-
ous variables and chi-square test for categorical
variables. All statistical analyses were performed using
SAS® software (v 9.3; SAS Institute, Cary, NC, USA).
Results
Patients’ disposition
Among 376 screened patients, 140 were assigned to
8-week treatments of FMS/RSV, FMS alone, or RSV
alone. After randomization, 24 patients discontinued
the study owing to consent withdrawal (n = 11),
protocol violation (n = 9), lack of efficacy (n = 2), ad-
verse events (n = 1), and other reasons (n = 1) (Fig. 1).
Of the 140 randomized patients, 135 were included in
primary efficacy analysis after excluding five patients
owing to missing efficacy data (Table 2). Their mean
age was 60.5 ± 8.7 years. The majority of the study
population comprised men (73.3%). The body mass
index of the FMS/RSV treatment group and siDBP of
the RSV alone treatment group were the highest among
the three groups. Other baseline characteristics were not
significantly different among the groups. Lipid-modifying
agents were taken by 93 patients (68.9%). Angiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers were taken by 81 patients (60.0%).
Efficacy
Changes in siSBP, siDBP and LDL-C are presented in
Table 3. FMS/RSV combination treatment had greater
Table 2 Baseline characteristics of the study population
Demographics Total
(n = 135)
FMS/RSV
(n = 46)
FMS
(n = 45)
RSV
(n = 44)
P-value
Age (year) 60.5 (8.7) 59.3 (8.7) 62.3 (9.5) 59.9 (7.7) 0.137a
Sex, men, n (%) 99 (73.3) 31 (67.4) 34 (75.6) 34 (77.3) 0.524b
Body mass index (kg/m2) 25.6 (2.7) 26.4 (2.8) 25.1 (2.6) 25.4 (2.8) 0.033a
Baseline blood pressure, mmHg
Systolic 152.8 (9.5) 152.5 (9.9) 151.3 (9.0) 154.7 (9.5) 0.157a
Diastolic 89.4 (9.1) 89.4 (8.3) 85.8 (9.3) 93.1 (8.5) 0.001a
Baseline Pulse Rate (beats/min) 75.2 (12.1) 76.4 (13.1) 73.0 (10.9) 76.2 (12.3) 0.441a
Baseline LDL-C (mg/dL) 165.7 (34.6) 171.3 (36.0) 164.1 (39.6) 161.4 (26.7) 0.294a
Smoking, n (%)
Current Smoker 37 (27.4) 14 (30.4) 12 (26.7) 11 (25.0) 0.933b
Non-smoker 57 (42.2) 17 (37.0) 2 0 (44.4) 20 (45.5)
Ex-smoker 41 (30.4) 15 (32.6) 13 (28.9) 13 (29.6)
Drinking, n (%)
Current drinker 83 (61.5) 30 (65.2) 27 (60.0) 26 (59.1) 0.811b
Non-drinker 52 (38.5) 16 (34.8) 18 (40.0) 18 (40.9)
Medication history of cardiovascular system, n (%)
Lipid modifying agents 93 (68.9) 31 (67.4) 34 (75.6) 28 (63.6)
ACE inhibitors or ARBs 81 (60.0) 28 (60.9) 29 (64.4) 24 (54.6)
Calcium channel blockers 38 (28.2) 9 (19.6) 13 (28.9) 16 (36.4)
Beta blockers 10 (7.4) 1 (2.2) 4 (8.9) 5 (11.4)
Cardiac drugs 7 (5.2) - 5 (11.1) 2 (4.6)
Diuretics 5 (3.7) 1 (2.2) 2 (4.4) 2 (4.6)
Peripheral vasodilators 4 (3.0) 1 (2.2) 3 (6.7) -
Vasoprotectives 1 (0.7) - - 1 (2.3)
Medical history, n (%)
Diabetes mellitus 33 (24.4) 8 (17.4) 16 (35.6) 9 (20.5)
Angina pectoris 6 (4.4) 1 (2.2) 2 (4.4) 3 (6.8)
Data are expressed as mean and standard deviation in parenthesis, and number and percent in parenthesis
FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, LDL-C low-density
lipoprotein cholesterol
Difference among treatment groups: aKruskal-Wallis test for continuous variables, bchi-square test for categorical variables
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efficacy in reducing siSBP from baseline after 8 weeks of
treatment compared to that reported for RSV alone
treatment (p < 0.001). Changes of siSBP was not signifi-
cantly different between FMS/RSV and FMS alone
groups (p = 0.500). Likewise, the reduction in siDBP
from baseline after 8 weeks of treatment was signifi-
cantly larger in the FMS/RSV treatment group compared
to that in the RSV alone treatment group (p < 0.001).
FMS/RSV and FMS alone treatments were not signifi-
cantly different in the reduction of siDBP (p = 0.734).
The least square mean (LSM) difference in siSBP and
siDBP between FMS/RSV and RSV alone treatment
groups was −15.03 mmHg (95% confidence interval:
−21.75 to −8.31 mmHg) and −8.95 mmHg (95% confi-
dence interval: −12.94 to −4.95 mmHg), respectively.
The percentage change of LDL-C from baseline to
after 8 weeks of treatment was larger in the FMS/RSV
treatment group than in the FMS alone treatment group
(p < 0.001). The percentage change of LDL-C between
the FMS/RSV and RSV alone treatment groups was not
different (p = 0.611). The LSM difference of LDL-C
percentage change between FMS/RSV and FMS alone
treatment groups was −46.91% (95% confidence inter-
val: −53.89 to −39.92%).
The response rate of siSBP, control rate of siSBP, and
goal attainment rate of LDL-C in FAS after 8 weeks of
treatment are presented in Fig. 2. The response rate of
siSBP in the FMS/RSV treatment, FMS alone treat-
ment, and RSV alone treatment groups was 65.22,
55.56, and 34.09%, respectively (FMS/RSV vs. RSV,
Table 3 Changes in sitting systolic blood pressure, sitting diastolic blood pressure and low-density lipoprotein cholesterol at Week 8
from baseline
Treatment groups FMS/RSV vs. FMS FMS/RSV vs. RSV
FMS/RSV
(N = 46)
FMS
(N = 45)
RSV
(N = 44)
LSM difference
(SE)
P-value LSM difference (SE) P-value
siSBP
Baseline 152.52 (9.85) 151.33 (8.99) 154.72 (9.46)
Week 8 132.05 (17.45) 134.63 (18.70) 150.21 (17.19)
Change −20.47 (15.60) −16.70 (16.54) −4.50 (15.50)
P-value <0.001a <0.001b 0.061a
ANCOVA results
LSM (SE) −21.89 (2.44) −19.61 (2.66) −6.86 (2.71) −2.28 (3.37) −15.03 (3.39)
(95% C.I.) (−26.71, −17.07) (−24.88, −14.35) (−12.22, −1.50) (−8.94, 4.39) 0.500d (−21.75, −8.31) <0.001d
siDBP
Baseline 89.42 (8.32) 85.78 (9.30) 93.08 (8.46)
Week 8 80.10 (10.47) 79.58 (8.47) 91.73 (11.46)
Change −9.32 (11.23) −6.20 (9.98) −1.35 (9.18)
P-value <0.001a 0.001a 0.335a
ANCOVA results
LSM (SE) −10.13 (1.42) −9.45 (1.59) −1.18 (1.61) −0.68 (1.98) −8.95 (2.02)
(95% C.I.) (−12.94, −7.31) (−12.60, −6.30) (−4.37, 2.01) (−4.60, 3.25) 0.734d (−12.94, −4.95) <0.001d
LDL-C
Baseline 171.33 (36.02) 164.09 (39.56) 161.39 (26.71)
Week 8 81.46 (27.10) 154.40 (52.37) 77.25 (23.33)
Percentage change −52.36 (12.97) −6.52 (20.48) −51.52 (15.80)
P-value <0.001b 0.112c <0.001c
ANCOVA results
LSM (SE) −52.74 (2.57) −5.83 (2.77) −50.92 (2.83) −46.91 (3.53) −1.82 (3.57)
(95% C.I.) (−57.82, −47.66) (−11.31, −0.35) (−56.52, −45.31) (−53.89, −39.92) <0.001d (−8.89, 5.24) 0.611d
FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, LDL-C low-density
lipoprotein, siSBP sitting systolic blood pressure, siDBP sitting diastolic blood pressure, SD standard deviation, LSM least square mean, SE standard error,
ANCOVA analysis of covariance
Percent change from baseline was compared by apaired t-test, bone sample t-test, or cWilcoxon signed rank test
dComparison between the combination therapy and monotherapy was analyzed by ANCOVA model adjusted for baseline values, age, gender and smoking status
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difference = 31.13%, 95% confidence interval 11.49 to
50.76, p = 0.012). The control rate of siSBP in FMS/
RSV treatment, FMS alone treatment, and RSV alone
treatment groups was 65.22, 55.56, and 29.55%, re-
spectively (FMS/RSV vs. RSV, difference = 35.67%, 95%
confidence interval 16.41 to 54.94, p = 0.003). The
goal attainment rate of LDL-C in the FMS/RSV treat-
ment, FMS alone treatment, and RSV alone treatment
groups was 80.43, 15.56, and 81.82%, respectively
(FMS/RSV vs. FMS, difference = 64.88%, 95% confidence
interval 49.27 to 80.49, p < 0.001). In PPS analysis, the re-
sponse and control rates of siSBP and siDBP, and the goal
attainment rate of LDL-C were similar to those from FAS
analysis (Table 4). The percentage of patients reaching
their siSBP and LDL-C therapeutic goals after FMS/RSV
treatment was 56.5%, which was higher than with FMS
alone treatment (4.44%, p < 0.001) or with RSV alone
treatment (25.0%, p = 0.003) (Fig. 3).
Similar to changes in LDL-C, FMS/RSV treatment also
showed a greater lowering effect on TC and triglyceride,
as well as HDL-C elevation compared to that reported
for FMS alone treatment (Table 5).
Safety and tolerability
In the safety set (n = 139) analysis, the incidence of
adverse events considered to be related to the study
drugs was 8.63% (n = 12, Table 6). There was no signifi-
cant difference in the incidence of study drug-related ad-
verse events between treatment groups. Adverse events
reported were dyspepsia (n = 1), nausea (n = 1), pyrexia
(n = 1), and hepatitis (n = 1) in the FMS/RSV treatment
group; upper abdominal pain (n = 1), elevation of hepatic
enzyme (n = 1), and pollakiuria (n = 1) in the FMS
alone treatment group; and headache (n = 2), hyperka-
lemia (n = 1), insomnia (n = 1), and pruritus (n = 1) in
the RSV alone treatment group. There was no serious
adverse event related to treatment with the study drugs.
Discussion
This study demonstrated that co-administration of FMS
and RSV for 8 weeks to patients with hypertension and
dyslipidemia was safe and effective in lowering blood
pressure and LDL-C. The blood pressure-lowering effect
of co-administration of FMS and RSV was not different
from that of the FMS alone treatment, but significantly
larger than that of the RSV alone treatment. The co-
administration of FMS and RSV lowered LDL-C levels
with similar effects as that of RSV alone treatment but
significantly greater effects than that of FMS alone treat-
ment. The response rates of siSBP and LDL-C upon co-
administration of FMS and RSV were stronger than that
after either RSV alone or FMS alone treatments.
Fimasartan is an antihypertensive drug that selectively
blocks the angiotensin II type 1 receptor. It is used as a
medication alone or in combination with other antihyper-
tensive drugs [13, 14]. Its safety and efficacy have been
proven [15, 17]. Rosuvastatin, an inhibitor of HMG-CoA
reductase, can reduce LDL-cholesterol more effectively
than other statins [18] with proven evidence for CVD pre-
vention [19]. The result of this study showed that there
was no interference between fimasartan and rosuvastatin
Fig. 2 (a) Response rate and (b) control rate of sitting systolic blood
pressure (siSBP), and (c) goal attainment rate of low-density lipoprotein
cholesterol (LDL-C) by fimasartan 120 mg/rosuvastatin 20 mg (FMS/
RSV) treatment, fimasartan 120 mg alone (FMS) treatment, and
rosuvastatin 20 mg alone (RSV) treatment at week 8. (Full analysis set)
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on the efficacy and the safety of both drugs when they
were simultaneously co-administered.
Although both antihypertensive drugs and statins have
robust evidences of effect regarding the prevention of
CVD, poor adherence to medications can reduce their
effects in clinical practice [8, 20]. Based on data analysis
of enrollees in the Korean National Health Insurance
system, poor adherence to treatment in patients with
hypertension has been found to be associated with
increased mortality and hospitalization [7]. Among the
study population, the proportion of hypertensive patients
with poor (cumulative medication adherence 50 – 80%)
and intermediate (cumulative medication adherence <80%)
adherence to antihypertensive medications was more than
60%. The association of long-term reduction of acute CVD
events with high adherence to antihypertensive treatments
was revealed based on the analysis of data obtained from
400 Italian primary care physicians [20], highlighting the
importance of adherence to treatment in the prevention of
CVD events.
Simplification of regimens by reducing the number of
drugs prescribed and the frequency of dosing is an
effective method to enhance patient’s adherence to treat-
ment [21, 22]. In a study evaluating patient adherence to
hypertension medications, adherence to medication was
inversely associated with the number of medications
included in the regimen [23]. The levels of adherence to
antihypertensive medications were 77.2%, 69.7%, 62.9%,
and 55.5% in patients receiving 1-, 2-, 3-, and 4-drug
regimens respectively. Single pill combination can
reduce the number of medications, and has been shown
to improve patient adherence to treatment by reducing
pill burden [9, 10]. Single pill combination has improved
compliance to medication by 21% and 26% compared to
free-drug component regimen [9, 10].
A limitation of this study is that age and gender differ-
ences in blood pressure and LDL-C lowering due to
different classes of antihypertensive drugs and rosuvasta-
tin were not considered in the study design. Angiotensin
converting enzyme inhibitors and beta blocker were
more effective compared to calcium channel blockers
and diuretics in lowering the blood pressure of young
hypertensive patients (age 28–55 years) [24]. In older
patients, calcium channel blockers and diuretics lowered
blood pressure more than angiotensin converting enzyme
Table 4 Response rate and control rate of sitting systolic blood pressure, and goal attainment rate of low-density lipoprotein
cholesterol by each treatment. (Analysis of per-protocol set)
Summary of each treatment FMS/RSV vs FMS FMS/RSV vs RSV
FMS/RSV FMS RSV Difference(SE) P-valued Difference(SE) P-valued
N = 35 N = 36) N = 37 (95% C.I.) (95% C.I.)
siSBP
Response ratea, n (%) 26 (74.29) 23 (63.89) 15 (40.54) 10.40 (10.89) 33.75 (10.94)
95% CI (59.81, 88.77) (48.20, 79.58) (24.72, 56.36) (−10.95, 31.75) 0.390 (12.30, 55.19) 0.010
Control rateb, n (%) 26 (74.29) 23 (63.89) 13 (35.14) 10.40 (10.89) 39.15 (10.78)
95% CI (59.81, 88.77) (48.20, 79.58) (19.75, 50.52) (−10.95, 31.75) 0.358 (18.03, 60.28) 0.003
LDL-C
Goal attainment ratec, n (%) 33 (94.29) 7 (19.44) 34 (91.89) 74.84 (7.67) 2.39 (5.96)
95% CI (86.60, 100.00) (6.52, 32.37) (83.10, 100.00) (59.80, 89.88) <0.001 (−21.13, 25.12) 0.082
FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, siSBP sitting systolic
blood pressure, LDL-C low-density lipoprotein cholesterol, CI confidence interval, SE standard error
aResponse Rate of siSBP: proportion of the subjects whose siSBP < 140 mmHg or Chang from Baseline of siSBP at Week 8 ≥ 20 mmHg
bControl rate of siSBP: proportion of the subjects whose siSBP < 140 mmHg
cGoal attainment rate of LDL-C: proportion of the subjects whose LDL-C < 100 mg/dL (high risk), LDL-C < 130 mg/dL (moderate high or moderate risk),
LDL-C < 160 mg/dL (low risk)
dComparison between combination therapy and monotherapy was analyzed by Logistic regression model adjusted for baseline values, age, and gender,
smoking status
Fig. 3 Percentage of patients who reached sitting systolic blood
pressure (siSBP) and low-density lipoprotein cholesterol (LDL-C) goals
after fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV) treatment,
fimasartan 120 mg alone (FMS) treatment, or rosuvastatin 20 mg
alone (RSV) treatment at week 8
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inhibitors [25]. A sex difference in blood pressure control
has been suggested in animal studies, but not in human
studies [26]. However, effect of age and gender differences
of angiotensin receptor blockers including fimasartan have
not been evaluated. The effect of age and gender differ-
ences of rosuvastatin in decreasing LDL-C is controversial.
A pharmacokinetic study of rosuvastatin showed a small
difference in plasma concentration between age and
gender groups [27]. However, this difference was not
considered clinically relevant because the difference was
statistically insignificant [27]. On the other hand, rosuvas-
tatin plasma levels were significantly higher in premeno-
pausal compared with postmenopausal women [28]. The
clinical significance of different plasma levels of rosuvasta-
tin is unclear because there is no controlled study evaluat-
ing the effect of age and gender difference of rosuvastatin
treatment in lowering LDL-C. Although this study was de-
signed without considering age and gender difference,
ANCOVA model showed the age and gender independent
efficacy of co-administered fimasartan and rosuvastatin.
Conclusion
The results of this study demonstrated that co-adminis-
tration of fimasartan and rosuvastatin to patients with
hypertension and hypercholesterolemia was efficacious
and safe. Therefore, a single pill combination of both
drugs is expected to be a suitable strategy for prevention
of CVD events.
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8 weeks of treatment
Summary of each treatment FMS/RSV vs. FMS FMS/RSV vs. RSV
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FMS
(N = 45)
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LSM difference (SE) P-valuea LSM difference (SE) P-valuea
Total cholesterol −36.13 (1.77) −3.62 (1.92) −35.99 (1.95) −32.51 (2.44) −0.14 (2.45)
95% CI (−39.63, −32.64) (−7.41, 0.17) (−39.86, −32.13) (−37.34, −27.69) <0.001 (−4.99, 4.71) 0.954
HDL-C 10.24 (2.63) −3.22 (2.86) 13.43 (2.95) 13.47 (3.63) −3.19 (3.67)
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20 mg alone treatment, LSM least square mean, SE standard error
aComparison between the combination therapy and monotherapy was analyzed by ANCOVA model adjusted for baseline values, age, gender and smoking status
Table 6 Incidence of drug related adverse events in safety
analysis population
Drug related adverse
events
Number (%) of subjects with ADRs
FMS/RSV MFS RSV p-value
Total number (%) 4 (8.33) 3 (6.52) 5 (11.11) 0.755
Abdominal pain upper - 1 (2.17) -
Dyspepsia 1 (2.08) - -
Nausea 1 (2.08) - -
Headache - - 2 (4.44)
Pyrexia 1 (2.08) - -
Hepatitis 1 (2.08) - -
Hepatic enzyme increased - 1 (2.17) -
Hyperkalaemia - - 1 (2.22)
Insomnia - - 1 (2.22)
Pollakiuria - 1 (2.17) -
Pruritus - - 1 (2.22)
ADRs adverse drug reactions, FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg
treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg
alone treatment
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